Cytokinetics to Hold Annual Meeting of Stockholders
Rhea-AI Summary
Cytokinetics (Nasdaq: CYTK) will hold its Annual Meeting of Stockholders on May 27, 2026 at 10:00 AM PT at its headquarters, 350 Oyster Point Blvd., South San Francisco, CA.
Stockholders of record on March 31, 2026 may vote in person or by proxy. A live and archived webcast will be available for 12 months.
Positive
- None.
Negative
- None.
News Market Reaction – CYTK
In the May 21 session, CYTK declined 0.90%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Scientific symposium | Neutral | +1.8% | Announcement of CLIMB 2026 muscle biology symposium and registration details. |
| May 12 | Conference participation | Neutral | +3.2% | Participation in 2026 RBC healthcare conference with a scheduled fireside chat. |
| May 11 | Clinical data update | Positive | -3.1% | New MYQORZO Phase 3 and real‑world data describing efficacy and safety signals. |
| May 08 | Equity offering close | Neutral | +3.5% | Closing of public stock offering with full exercise of underwriters’ option. |
| May 06 | Equity offering pricing | Neutral | -0.7% | Pricing of upsized common stock offering under existing shelf registration. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent stock responses to non-fundamental news (conferences, events) have produced modest single-day moves, while a positive clinical update showed a negative price reaction.
Over the past weeks, Cytokinetics has issued several event-driven updates, including a CLIMB muscle biology symposium on May 29, 2026 and participation in the 2026 RBC Global Healthcare Conference, which saw modest positive moves of 1.84% and 3.22%. A data update on MYQORZO from multiple Phase 3 and real‑world studies on May 11, 2026 coincided with a -3.06% reaction. Two common stock offerings in early May raised substantial capital but produced limited single‑day price shifts. Today’s annual meeting notice fits this pattern of largely procedural communications.
Key Terms
proxy card financial
proxy statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance.
Stockholders of record at the close of business on March 31, 2026, are entitled to vote at Cytokinetics’ Annual Meeting of Stockholders or to attend in person and submit questions to management. Stockholders wishing to vote must attend the meeting in person or submit a valid proxy card by mail, telephone or internet by 11:59 PM Eastern Time on May 26, 2026, in accordance with instructions contained in our Proxy Statement for the 2026 Annual Meeting of Stockholders.
Interested parties may access the live webcast of the Annual Meeting of Stockholders and the subsequent presentation at the following link: Cytokinetics Annual Meeting of Stockholders. An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company is preparing to present the full results at an upcoming medical meeting and discuss them with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Disclaimer
Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
+1 (415) 290-7757
